Cyclin-dependent kinase 4 (CDK4) and CDK6 are dysregulated in cancer cells and many preclinical studies have demonstrated the hyperactivity of the cyclin D–CDK4/6 axis, rendering CDK inhibitors as desirable therapeutic approaches [191,192,193]. The gene discussed is CDK4; the disease is cancer.